Product Details
| Product Name: 2-[4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid | CAS No.: 516-50-7 |
| Min. Order: 1kg | Purity: 99.99 |
| Supply Ability: 10000 | Release date: 2025/11/28 |
Chemical Properties
| Melting point | 175-200 °C |
| Density | 1.216±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated, Sonicated) |
| form | Solid |
| pka | 1.42±0.50(Predicted) |
| color | White to Off-White |
| Stability | Hygroscopic |
Usage And Synthesis
Taurodeoxycholic acid (1.25-5 mg/kg, p.o., 6 days) ameliorates dextran sodium sulfate (DSS)-induced colitis in mice[9].
Taurodeoxycholic acid (Taurodeoxycholic acid form, 50 mg/kg; i.p.; once daliy for 34 d) prevents neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of Huntington's disease (HD) [10].
Taurodeoxycholic acid (Taurodeoxycholic acid form, 500 mg/kg; s.c.; once every 3 d for 7 weeks) leads to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse[11].
Taurodeoxycholic acid (0.5 mg/kg; i.v., once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[12].
| Animal Model: | A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9] |
| Dosage: | 1.25, 2.5, and 5 mg/kg |
| Administration: | Oral gavage (p.o.), from day 3 to day 8, once a day |
| Result: | Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon. |
| Animal Model: | Huntington's disease model in mouse[10] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment |
| Result: | Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions. Significantly improved locomotor and sensorimotor deficits. |
| Animal Model: | C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12] |
| Dosage: | 0.5 mg/kg |
| Administration: | Intravenous injection, 30 min or 24 h after LPS injection |
| Result: | Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice. |
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-17 | |
| $0.00/200kg |
VIP2Y
|
Qingdao RENAS Polymer Material Co., Ltd.
|
2024-10-14 | |
| $8.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-01-22 | |
| $48.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-12-02 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-21 |
- Since: 2024-12-18
- Address: No. 32 Binhai Avenue, Longhua District, Haikou City, Hainan Province, China

China